BlackRock and Eclipse led a $257m series D round in Cellares.

BlackRock, a global investment management corporation, and Eclipse, a venture capital firm, led a $257m series D round in Cellares, an integrated development and manufacturing organization focused on the automated, large-scale manufacture of cell therapies, with participation from T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors. ​“Cellares is building the high-tech, industrial backbone required for cell therapy to scale globally. Validated and cutting-edge automation, regulatory recognition, and growing commercial demand make Cellares a category‑defining platform in a rapidly growing global market projected to reach tens of billions of dollars per year over the coming decade,” Andrew Farris, BlackRock Managing Director.